Semaglutide

Overview

Semaglutide is a modified glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1. Developed by Novo Nordisk, it has achieved FDA approval under three brand names: Ozempic (type 2 diabetes, 2017), Rybelsus (oral formulation for type 2 diabetes, 2019), and Wegovy (chronic weight management, 2021). Semaglutide represents one of the most impactful pharmacologic advances in metabolic medicine in the past decade, with demonstrated benefits for glycemic control, weight reduction, and cardiovascular risk.

The molecule features a C-18 fatty diacid chain attached via a linker to position 26, enabling binding to albumin in the bloodstream. This structural modification extends the half-life to approximately 7 days, allowing once-weekly subcutaneous dosing. The oral formulation (Rybelsus) co-formulates semaglutide with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to facilitate gastric absorption. Semaglutide is also available through 503A compounding pharmacies, though compounded versions are not FDA-approved.

Mechanism of Action

Semaglutide activates the GLP-1 receptor, a G-protein coupled receptor expressed in the pancreatic beta cells, gastrointestinal tract, heart, kidneys, and central nervous system. This activation triggers multiple downstream effects that collectively address the core pathophysiology of type 2 diabetes and obesity.

In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion--meaning insulin release increases only when blood glucose is elevated, which substantially reduces hypoglycemia risk compared to sulfonylureas or exogenous insulin. Simultaneously, semaglutide suppresses inappropriate glucagon secretion from alpha cells, further improving postprandial glucose control.

The weight loss effects arise primarily from central appetite regulation. Semaglutide acts on GLP-1 receptors in the hypothalamic arcuate nucleus and other appetite-regulating centers, reducing hunger, increasing satiety, and diminishing food reward signaling. Additionally, the peptide slows gastric emptying, contributing to both glucose reduction and increased fullness after meals.

• Glucose-dependent insulin secretion: Enhances beta-cell insulin release only during hyperglycemia
• Glucagon suppression: Reduces inappropriate postprandial glucagon release
• Appetite regulation: Acts on hypothalamic centers to reduce hunger and food cravings
• Delayed gastric emptying: Slows nutrient delivery to the small intestine
• Cardiovascular protection: Reduces inflammation, oxidative stress, and atherosclerotic progression
• Beta-cell preservation: Evidence of improved beta-cell function and reduced apoptosis

Clinical Applications

Primary Indications

Semaglutide has two distinct FDA-approved indication categories. For type 2 diabetes (as Ozempic or Rybelsus), it is indicated as an adjunct to diet and exercise to improve glycemic control, with demonstrated HbA1c reductions of 1.5-1.8% in clinical trials. For chronic weight management (as Wegovy), it is approved for adults with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity, where it produces average weight loss of 15-17% over 68 weeks.

• Type 2 diabetes with inadequate glycemic control on metformin or lifestyle alone
• Chronic weight management (BMI 30+, or BMI 27+ with comorbidity)
• Cardiovascular risk reduction in type 2 diabetes patients
• Patients who require or prefer once-weekly injection convenience

Secondary / Off-Label Uses

Emerging evidence supports semaglutide's potential benefit in several conditions beyond its approved indications. Research is active in non-alcoholic steatohepatitis (NASH), where semaglutide has shown histologic improvement in liver inflammation and fibrosis. Interest is also growing in its effects on heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea, polycystic ovary syndrome, and addictive behaviors.

• NAFLD/NASH (histologic improvement demonstrated in phase 2 trials)
• Heart failure with preserved ejection fraction (STEP-HFpEF trial positive)
• Polycystic ovary syndrome (PCOS) with metabolic features
• Obstructive sleep apnea (weight-mediated improvement)
• Metabolic syndrome components (dyslipidemia, hypertension)

Dosing & Administration

Administration Tips

Semaglutide should be stored refrigerated at 2-8 degrees C prior to first use. After first use, the pen can be stored at room temperature (up to 30 degrees C) or refrigerated for up to 56 days. For patients experiencing significant GI side effects during titration, recommend smaller and more frequent meals, avoiding high-fat foods, staying well-hydrated, and eating slowly. If nausea is severe, extending the titration period by holding at the current dose for an additional 4 weeks is preferable to discontinuation.

Safety Considerations

Common Side Effects

Gastrointestinal effects are the most common adverse events and are typically most pronounced during dose escalation. They generally diminish over 4-8 weeks at each dose level.

• Nausea: 20-44% (most common; typically peaks during first 1-2 weeks of each dose increase)
• Diarrhea: 15-30%
• Vomiting: 5-24%
• Constipation: 5-24%
• Abdominal pain: 5-20%
• Headache: 10-14%
• Injection site reactions: 1-5% (mild)

Drug Interactions

Semaglutide slows gastric emptying, which can delay absorption of co-administered oral medications. Key interactions include:

• Insulin and sulfonylureas: Increased hypoglycemia risk; reduce sulfonylurea dose by 50% when initiating semaglutide and monitor insulin needs closely
• Oral contraceptives: Delayed absorption possible; recommend taking at least 1 hour before semaglutide injection or switching to non-oral contraception
• Warfarin: Altered absorption kinetics; increase INR monitoring frequency when starting or adjusting semaglutide
• Narrow therapeutic index drugs: Monitor levels of medications like levothyroxine, digoxin, and phenytoin during initiation and titration
• Other GLP-1 agonists: Do not combine; no additive benefit and increased GI adverse effects

Evidence Summary

Semaglutide has one of the most robust evidence bases of any peptide therapy, supported by multiple large, randomized, double-blind, placebo-controlled trials. The SUSTAIN program (7 trials) established its efficacy and safety for type 2 diabetes, while the STEP program (5+ trials) validated its role in weight management. The SELECT trial (n=17,604) confirmed cardiovascular benefit in overweight/obese patients without diabetes.

Key efficacy benchmarks from pivotal trials include HbA1c reduction of 1.5-1.8% (SUSTAIN trials), weight loss of 14.9% vs. 2.4% placebo at 68 weeks (STEP 1), and 20% reduction in MACE in the SELECT trial. Head-to-head data show semaglutide's superiority over other GLP-1 agonists (liraglutide, dulaglutide, exenatide) for both glycemic and weight endpoints.

Regulatory Status

Semaglutide is FDA-approved under three brand names: Ozempic (type 2 diabetes, injectable), Rybelsus (type 2 diabetes, oral), and Wegovy (chronic weight management, injectable). It is also available through compounding pharmacies; however, compounded semaglutide is not FDA-approved and may differ in purity, potency, and bioavailability. The FDA has issued warnings about compounded semaglutide products, including concerns about salt forms (semaglutide sodium vs. semaglutide base). Prescribers using compounded formulations should document informed consent regarding the non-FDA-approved status and ensure sourcing from reputable 503A or 503B facilities with certificates of analysis.